Janet Woodcock Retires From US FDA: ‘I’m Trying To Tie Up All The Loose Ends’
On the eve of departure after more than 37 years of service to FDA, the agency’s principal deputy commissioner discusses her legacy, issues that others will take up, and preparing the agency for change in a Pink Sheet interview.
You may also be interested in...
The Pink Sheet offers a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.
US FDA's response time and decision consistency on compliance issues should improve under reorganization that aims to take agency processes into the modern era. FDA is already moving forward on steps needed to implement the reorg as it awaits HHS and White House approval.
The FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues told the Pink Sheet.